Indication
Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Fosavance reduces the risk of vertebral and hip fractures.
Loading your page…
Loading your page…
Osteoporosis, Postmenopausal
Marketing Authorisation Holder: Organon N.V.
EMA Authorisation: 24/08/2005
INN: alendronic acid;colecalciferol
AI Drug & Interaction Analysis
Free account required
Ask Osler about Fosavance: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.